

Supplementary Table 1 Summary of > 2% adverse events by System Organ Class and Preferred Term (safety set), *n* (%), events

	Lurasidone (40 mg/day), <i>n</i> = 99	Lurasidone (80 mg/day), <i>n</i> = 98
Total TEAEs	64 (64.6), 182	70 (71.4), 178
Nervous system disorders	29 (29.3), 45	44 (44.9), 62
Akathisia	19 (19.2), 23	26 (26.5), 28
Tremor	3 (3.0), 3	8 (8.2), 8
Psychiatric disorders	18 (18.2), 22	21 (21.4), 25
Insomnia	8 (8.1), 10	8 (8.2), 10
Investigations	18 (18.2), 24	17 (17.3), 20
Blood prolactin increased	7 (7.1), 7	13 (13.3), 13
Gastrointestinal disorders	17 (17.2), 30	13 (13.3), 18
Nausea	9 (9.1), 13	4 (4.1), 4
Infections and infestations	12 (12.1), 12	12 (12.2), 13
Nasopharyngitis	3 (3.0), 3	7 (7.1), 8
General disorders and administration site conditions	8 (8.1), 8	7 (7.1), 8

TEAE: Treatment-emergent adverse events.

Supplementary Table 2 Proportion of subjects treated for 6 Weeks shifted from normal to clinically significant abnormal (safety set), *n* (%)

	Lurasidone (40 mg/day), <i>n</i> = 99	Lurasidone (80 mg/day), <i>n</i> = 98
Measure		
ALT (U/L)	4 (4.0)	2 (2.0)
AST (U/L)	2 (2.0)	2 (2.0)
Serum creatinine (μmol/L)	0	0
Serum prolactin (ng/ml)	5 (5.1)	5 (5.1)
Fasting blood glucose (mmol/L)	0	2 (2.0)
Total cholesterol (mmol/L)	1 (1.0)	0
Triglycerides (mmol/L)	1(1.0)	1(1.0)
HDL cholesterol (mmol/L)	0	1(1.0)
LDL cholesterol (mmol/L)	0	0
ECG	1 (1.0)	3 (3.1)

ALT: Alanine transaminase; AST: Aspartate transaminase; HDL: High density lipoprotein; LDL: Low density lipoprotein; ECG: Electrocardiogram.

Supplementary Table 3 Change from baseline to all visit points for efficacy measures (full analysis set), mean $\pm$ SD

		Lurasidone (40 mg/day), <i>n</i> = 99	Lurasidone (80 mg/day), <i>n</i> = 98
PANSS			
Total change	Visit 1	-14.2 $\pm$ 12.97 ^b	-17.2 $\pm$ 15.38 ^b
	Visit 2	-20.5 $\pm$ 16.19 ^b	-25.2 $\pm$ 17.03 ^b
	Visit 3	-25.8 $\pm$ 17.61 ^b	-29.5 $\pm$ 9.01 ^b
	Visit 4	-30.3 $\pm$ 17.92 ^b	-33.4 $\pm$ 20.90 ^b
Positive subscale change	Visit 1	-4.2 $\pm$ 4.24 ^b	-5.6 $\pm$ 5.46 ^b
	Visit 2	-6.7 $\pm$ 5.22 ^b	-8.2 $\pm$ 5.68 ^b
	Visit 3	-8.4 $\pm$ 6.16 ^b	-9.0 $\pm$ 6.41 ^b
	Visit 4	-9.8 $\pm$ 6.23 ^b	-10.2 $\pm$ 6.62 ^b
Negative subscale change	Visit 1	-3.3 $\pm$ 3.95 ^b	-3.6 $\pm$ 4.54 ^b
	Visit 2	-4.4 $\pm$ 5.18 ^b	-5.8 $\pm$ 5.23 ^b
	Visit 3	-5.3 $\pm$ 5.31 ^b	-6.6 $\pm$ 5.90 ^b
	Visit 4	-6.3 $\pm$ 5.89 ^b	-7.9 $\pm$ 6.55 ^b
General psychopathology subscale	Visit 1	-6.7 $\pm$ 7.22 ^b	-8.0 $\pm$ 8.18 ^b
	Visit 2	-9.4 $\pm$ 8.95 ^b	-11.2 $\pm$ 9.49 ^b

	Visit 3	-12.1 ± 9.83 ^b	-13.9 ± 10.16 ^b
	Visit 4	-14.1 ± 9.28 ^b	-15.3 ± 10.77 ^b
PANSS 5-factor			
Positive factor score change	Visit 1	-2.4 ± 2.65 ^b	-2.8 ± 3.13 ^b
	Visit 2	-4.1 ± 3.34 ^b	-4.7 ± 3.57 ^b
	Visit 3	-5.3 ± 4.34 ^b	-5.3 ± 3.83 ^b
	Visit 4	-6.3 ± 4.34 ^b	-6.0 ± 4.27 ^b
Negative factor score change	Visit 1	-3.1 ± 3.82 ^b	-3.2 ± 4.43 ^b
	Visit 2	-3.7 ± 5.31 ^b	-5.0 ± 5.03 ^b
	Visit 3	-4.7 ± 5.55 ^b	-5.9 ± 5.56 ^b
	Visit 4	-5.7 ± 5.89 ^b	-7.3 ± 6.33 ^b
Cognitive scale score change	Visit 1	-1.0 ± 1.74 ^b	-1.8 ± 2.29 ^b
	Visit 2	-1.7 ± 2.20 ^b	-2.7 ± 2.74 ^b
	Visit 3	-2.0 ± 2.23 ^b	-3.2 ± 2.84 ^b
	Visit 4	-2.3 ± 2.58 ^b	-3.5 ± 2.79 ^b
Excitation scale score change	Visit 1	-2.1 ± 3.57 ^b	-3.0 ± 4.06 ^b
	Visit 2	-2.8 ± 3.95 ^b	-3.7 ± 3.95 ^b

	Visit 3	-3.4 ± 3.89 ^b	-4.0 ± 4.33 ^b
	Visit 4	-3.7 ± 3.95 ^b	-4.2 ± 4.61 ^b
Depression and anxiety scale score change	Visit 1	-1.3 ± 2.11 ^b	-1.2 ± 1.94 ^b
	Visit 2	-1.7 ± 2.55 ^b	-1.4 ± 2.46 ^b
	Visit 3	-2.1 ± 2.81 ^b	-1.7 ± 2.49 ^b
	Visit 4	-2.3 ± 2.74 ^b	-1.9 ± 2.65 ^b
CGI-S score change	Visit 1	-0.7 ± 1.03 ^b	-0.8 ± 1.28 ^b
	Visit 2	-1.1 ± 1.01 ^b	-1.3 ± 1.30 ^b
	Visit 3	-1.6 ± 1.25 ^b	-1.7 ± 1.46 ^b
	Visit 4	-1.9 ± 1.28 ^b	-2.0 ± 1.59 ^b
CDSS score change	Visit 1	-1.7 ± 3.25 ^b	-0.9 ± 2.70 ^a
	Visit 2	-2.1 ± 3.64 ^b	-1.0 ± 3.71 ^a
	Visit 3	-2.2 ± 3.95 ^b	-1.2 ± 3.22 ^b
	Visit 4	-2.4 ± 3.71 ^b	-1.2 ± 3.44 ^b

^a $P < 0.01$.

^b $P < 0.001$.

PANSS: Positive and Negative Syndrome Scale; CGI-S: Clinical Global Impression Scale–Severity; CDSS: Calgary Depression Scale

for Schizophrenia.